We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Predatory Bacteria Found in Lung Microbiome of CF Patient

By LabMedica International staff writers
Posted on 10 Oct 2017
The natural evolution of cystic fibrosis (CF) is a progressive decline in lung function caused by a vicious circle of inflammation and tissue destruction, which is triggered and maintained by the chronic bacterial colonization of the lower respiratory tract.

The introduction of culture-independent tools, particularly those based on next-generation sequencing (NGS), has allowed the identification of a more diverse and abundant lung microbiota that includes not only classical CF pathogens but also a wide community of bacterial taxa, most of which are uncultivable by routine methods.

Medical scientists at the Ramón y Cayal University Hospital (Madrid, Spain) and their colleagues analyzed 56 sputum samples from 15 cystic fibrosis patients at the hospital. More...
Patients were classified by lung function impairment as mild (five patients), moderate (nine patients), or severe (one patient). Sputum samples were routinely aerobically cultured in accordance with the recommendations of the Spanish CF guidelines. All colonies, except for those of Burkholderia cepacia complex, were identified by matrix-assisted laser desorption ionization time of flight mass spectrometry.

The sputum samples were slowly defrosted at 4 °C for 24 hours to prevent DNA degradation and further thawed at room temperature. After complete vortex mixing of the sample, total DNA was obtained from an aliquot of ~0.5 mL of the supernatant with the QIAamp DNA minikit. DNA samples were sent for massive 16S rRNA gene V3-V4 amplicon sequencing on the MiSeq platform and for bioinformatic analysis.

The team found a wide range of 156 types of bacterial species in the samples, including Pseudomonas aeruginosa, Staphylococcus aureus, Burkholderia and Pandorea. Each patient had his or her own bacterial makeup that remained relatively steady over the study period. They also found two types of predator bacteria among the samples. Vampirovibrio, a bacterium that destroys cells by sucking out its contents, was found in 17 samples from 12 patients, while Bdellovibrio, which enters cells and feeds on its proteins, was found in six samples from three patients. The two types were found together in only one patient.

Rosa del Campo, MD, PhD, the senior author of the study, said, “Predator bacteria are ubiquitous and are usually found in environmental aquatic ecosystems. In humans, a recent study has found them in the intestinal microbiota of healthy individuals and in patients with cystic fibrosis. The findings indicate that the lung microbiota in cystic fibrosis patients is more complex than we believed. Our study suggests that predatory bacteria could be used as a therapeutic strategy to reduce the bacterial load of the lungs of these patients.” The study was published on September 26, 2017, in the journal mBIO.

Related Links:
Ramón y Cayal University Hospital


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
PlGF Test
Quidel Triage PlGF Test
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.